Articles published by Veracyte, Inc.
![](https://mms.businesswire.com/media/20220526005768/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220526005254/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte to Present at Upcoming Investor Conferences
May 26, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20220516006017/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220512006072/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220504005302/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
May 04, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20220503005909/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220502005830/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220428006287/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference
April 28, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20220426006197/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220419005345/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220228005304/en/1372889/4/Annie_McGuire_Photo.jpg)
Veracyte Appoints Annie McGuire as General Counsel
February 28, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20220222005393/en/1366289/4/Jonathan_Wygant_High-Res_Photo.jpg)
Veracyte Appoints Jonathan Wygant as Chief Accounting Officer
February 22, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20220215005571/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022
February 15, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20220214005875/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220208006191/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220131005226/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium
January 31, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20220124005229/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220106005359/en/1320412/4/Giulia_Kennedy_2021.jpg)
Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision
January 06, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20211214005928/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20211124005892/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test
November 24, 2021
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20211113005235/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20211109006376/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte Announces Third Quarter 2021 Financial Results
November 09, 2021
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20211105005245/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
November 05, 2021
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20211103005432/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
November 03, 2021
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20211102005538/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities
November 02, 2021
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20211026005605/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20211025005198/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20211014005393/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20211013005673/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20211012006039/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.